CS
SPRY icon

Candriam SCA’s ARS Pharmaceuticals SPRY Stock Holding History

Candriam SCA’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-196,557
Closed -$6.07M – 906
2021
Q2 		$6.07M Buy
196,557
+196,544
+1,511,877% +$6.3M 0.04% 370
2021
Q1 		$1K Buy
+13
New +$615 ﹤0.01% 802

Other funds holding SPRY

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Candriam SCA's SPRY Position: Q3 2021 in Review

Candriam SCA sold out of ARS Pharmaceuticals (SPRY) in Q3 2021, closing a stake of 196,557 shares — an estimated $6.07M sold.

Candriam SCA first reported a position in SPRY in Q1 2021 and held it in 2 quarters. The position peaked at $6.07M in Q2 2021. 74 funds tracked by Wall St. Rank hold SPRY as of Q3 2021.

  • Candriam SCA reported no remaining ARS Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Candriam SCA sold 196,557 ARS Pharmaceuticals shares in Q3 2021, an estimated $6.07M.
  • Candriam SCA first reported a position in ARS Pharmaceuticals in Q1 2021 and held it in 2 quarters.
  • Candriam SCA's ARS Pharmaceuticals position peaked at $6.07M in Q2 2021.
  • 74 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2021.

Based on Candriam SCA's 13F filing for Q3 2021, filed 9 Nov 2021.